Flunarizine Hydrochloride Capsules

Flunarizine hydrochloride is a selective calcium antagonist that can block excessive calcium ions from entering cells across the membrane, preventing excessive intracellular calcium load. It can also prevent a large amount of calcium from entering neurons during ischemia and hypoxia, improve brain microcirculation and neuronal metabolism, inhibit cerebral vasospasm, platelet aggregation and increased blood viscosity, and also has a cell membrane stabilizing effect. This product is highly lipid-soluble and easily penetrates the blood-brain barrier. This product has no effect on cardiac contraction and conduction.

Flunarizine hydrochloride Chemical name: (E)-1-[bis(4-fluorophenyl)methyl]-4-(2-propenyl-3-phenyl)-piperazine dihydrochloride Molecular formula: C26H26F2N22HCL Molecular weight: 477.42.

This product is a capsule containing white or off-white powder.

1. Preventive treatment of typical (with aura) or atypical (without aura) migraine; 2. Symptomatic treatment of vertigo caused by vestibular dysfunction.

1. Preventive treatment of migraine. Starting dose: 10 mg per night for patients under 65 years old, 5 mg per night for patients over 65 years old. Maintenance treatment: If the efficacy is satisfactory and the patient needs maintenance treatment, the dose should be reduced to five days per week (same dose as above). 2. Vertigo: The daily dose should be the same as above, but the drug should be discontinued in time after the symptoms are controlled. The initial course of treatment is usually less than 2 months.

1. The most common adverse reactions (often transient) are: drowsiness and/or fatigue (20%), and some patients may also experience weight gain (and/or increased appetite) (11%). 2. The following serious adverse reactions are occasionally seen (seen in long-term users): depression, which is more likely to occur in female patients with a history of depression. Extrapyramidal symptoms (such as bradykinesia, rigidity, akathisia, oral and mandibular movement disorders, tremors, etc.) are more likely to occur in the elderly. 3. Rare adverse reactions reported include: Gastrointestinal reactions: heartburn, nausea, stomach pain. Central nervous system: insomnia, anxiety. 4. Others: galactorrhea, dry mouth, muscle pain and rash.

This product is contraindicated in patients with a history of depression, Parkinson's disease or other symptoms of extrapyramidal disorders.

Precautions for children: Since this drug can pass through the blood-brain barrier, it has clear adverse reactions in the central nervous system and the central nervous system of children is sensitive to the drug; the metabolic function is relatively weak. Although there is no detailed research data on the use of drugs in children, in principle, children should be cautious or avoid using this drug. Precautions for pregnancy and lactation: Since this drug can pass through the placental barrier and can be secreted with breast milk, although there are no reports of teratogenicity and effects on embryonic development, in principle, pregnant women and lactating women should not use this drug. Precautions for the elderly: Since the nervous system of elderly patients is more sensitive and their metabolic capacity is weaker, the dosage should be reduced as appropriate.

When this product is used in combination with alcohol, hypnotics or sedatives, excessive sedation may occur. This product is not contraindicated for patients using beta-receptor blockers.

Keep away from light and store in sealed container.

5 mg (calculated as C26H26F2N2)

36 months

Xian Janssen Pharmaceutical Ltd.

• Founded in:

  1985-10-22

• Address:

  No. 19, Caotang 4th Road, Caotang Science and Technology Industrial Base, High-tech Zone, Xi'an, Shaanxi Province, 17F, Huicheng International, No. 4, Gaoxin 5th Road, High-tech Zone, Xi'an, Shaanxi Province

• Tax NO.:

  91610000623100825C

• Registered Funds:

  284.317164 yuan

• Website:

  Log in to view

• Email:

  Log in to view